Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2014

Open Access 01-12-2014 | Research article

Genomic investigation of etiologic heterogeneity: methodologic challenges

Authors: Colin B Begg, Venkatraman E Seshan, Emily C Zabor, Helena Furberg, Arshi Arora, Ronglai Shen, Jodi K Maranchie, Matthew E Nielsen, W Kimryn Rathmell, Sabina Signoretti, Pheroze Tamboli, Jose A Karam, Toni K Choueiri, A Ari Hakimi, James J Hsieh

Published in: BMC Medical Research Methodology | Issue 1/2014

Login to get access

Abstract

Background

The etiologic heterogeneity of cancer has traditionally been investigated by comparing risk factor frequencies within candidate sub-types, defined for example by histology or by distinct tumor markers of interest. Increasingly tumors are being profiled for molecular features much more extensively. This greatly expands the opportunities for defining distinct sub-types. In this article we describe an exploratory analysis of the etiologic heterogeneity of clear cell kidney cancer. Data are available on the primary known risk factors for kidney cancer, while the tumors are characterized on a genome-wide basis using expression, methylation, copy number and mutational profiles.

Methods

We use a novel clustering strategy to identify sub-types. This is accomplished independently for the expression, methylation and copy number profiles. The goals are to identify tumor sub-types that are etiologically distinct, to identify the risk factors that define specific sub-types, and to endeavor to characterize the key genes that appear to represent the principal features of the distinct sub-types.

Results

The analysis reveals strong evidence that gender represents an important factor that distinguishes disease sub-types. The sub-types defined using expression data and methylation data demonstrate considerable congruence and are also clearly correlated with mutations in important cancer genes. These sub-types are also strongly correlated with survival. The complexity of the data presents many analytical challenges including, prominently, the risk of false discovery.

Conclusions

Genomic profiling of tumors offers the opportunity to identify etiologically distinct sub-types, paving the way for a more refined understanding of cancer etiology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Harris TJ, McCormick F: The molecular pathology of cancer. Nat Rev Clin Oncol. 2010, 7 (5): 251-265. 10.1038/nrclinonc.2010.41.CrossRefPubMed Harris TJ, McCormick F: The molecular pathology of cancer. Nat Rev Clin Oncol. 2010, 7 (5): 251-265. 10.1038/nrclinonc.2010.41.CrossRefPubMed
2.
go back to reference Schouten LJ, van Dijk BA, Oosterwijk E, Hulsbergen Van De Kaa CA, Kiemeney LA, Goldbohm RA, Schalken JA, Van Den Brandt PA: Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands cohort study. J Hypertens. 2005, 23 (11): 1997-2004. 10.1097/01.hjh.0000186023.74245.48.CrossRefPubMed Schouten LJ, van Dijk BA, Oosterwijk E, Hulsbergen Van De Kaa CA, Kiemeney LA, Goldbohm RA, Schalken JA, Van Den Brandt PA: Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands cohort study. J Hypertens. 2005, 23 (11): 1997-2004. 10.1097/01.hjh.0000186023.74245.48.CrossRefPubMed
3.
go back to reference van Dijk BA, Schouten LJ, Oosterwijk E, Hulsbergen Van De Kaa CA, Kiemeney LA, Goldbohm RA, Schalken JA, Van Den Brandt PA: Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Br J Cancer. 2006, 95 (3): 374-377. 10.1038/sj.bjc.6603281.CrossRefPubMedPubMedCentral van Dijk BA, Schouten LJ, Oosterwijk E, Hulsbergen Van De Kaa CA, Kiemeney LA, Goldbohm RA, Schalken JA, Van Den Brandt PA: Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Br J Cancer. 2006, 95 (3): 374-377. 10.1038/sj.bjc.6603281.CrossRefPubMedPubMedCentral
4.
go back to reference Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N: Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011, 7 (10): e1002312-10.1371/journal.pgen.1002312.CrossRefPubMedPubMedCentral Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N: Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011, 7 (10): e1002312-10.1371/journal.pgen.1002312.CrossRefPubMedPubMedCentral
6.
go back to reference Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E: Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host and disease. Mod Pathol. 2013, 26 (4): 465-484. 10.1038/modpathol.2012.214.CrossRefPubMedPubMedCentral Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E: Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host and disease. Mod Pathol. 2013, 26 (4): 465-484. 10.1038/modpathol.2012.214.CrossRefPubMedPubMedCentral
7.
go back to reference Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE: A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013, 32 (29): 5039-5052. 10.1002/sim.5902.CrossRefPubMedPubMedCentral Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE: A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013, 32 (29): 5039-5052. 10.1002/sim.5902.CrossRefPubMedPubMedCentral
8.
go back to reference Cancer and Steroid Hormone Study Investigators: Oral-contraceptive use and the risk of breast cancer. The cancer and steroid hormone study of the centers for disease control and the National Institute of child health and human development. N Engl J Med. 1986, 315 (7): 405-411.CrossRef Cancer and Steroid Hormone Study Investigators: Oral-contraceptive use and the risk of breast cancer. The cancer and steroid hormone study of the centers for disease control and the National Institute of child health and human development. N Engl J Med. 1986, 315 (7): 405-411.CrossRef
9.
go back to reference Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Deapen DM, Ursin G, Coates RJ, Simon MS, Press MF, Spirtas R: The NICHD womens’ contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol. 2002, 12 (4): 213-221. 10.1016/S1047-2797(01)00274-5.CrossRefPubMed Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Deapen DM, Ursin G, Coates RJ, Simon MS, Press MF, Spirtas R: The NICHD womens’ contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol. 2002, 12 (4): 213-221. 10.1016/S1047-2797(01)00274-5.CrossRefPubMed
10.
go back to reference Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013, 499 (7456): 43-49. 10.1038/nature12222.CrossRef Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013, 499 (7456): 43-49. 10.1038/nature12222.CrossRef
11.
go back to reference Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E: Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013, 190 (5): 1657-1661. 10.1016/j.juro.2013.04.130.CrossRefPubMedPubMedCentral Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E: Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013, 190 (5): 1657-1661. 10.1016/j.juro.2013.04.130.CrossRefPubMedPubMedCentral
12.
go back to reference McGuire BB, Fitzpatrick JM: BMI and the risk of renal cell carcinoma. Curr Opin Urol. 2011, 21 (5): 356-361. 10.1097/MOU.0b013e32834962d5.CrossRefPubMed McGuire BB, Fitzpatrick JM: BMI and the risk of renal cell carcinoma. Curr Opin Urol. 2011, 21 (5): 356-361. 10.1097/MOU.0b013e32834962d5.CrossRefPubMed
13.
go back to reference Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P: Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005, 114 (1): 101-108. 10.1002/ijc.20618.CrossRefPubMed Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P: Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005, 114 (1): 101-108. 10.1002/ijc.20618.CrossRefPubMed
14.
go back to reference Grossman E, Messerli FH, Boyko V, Goldbourt U: Is there an association between hypertension and cancer mortality?. Am J Med. 2002, 112 (6): 479-486. 10.1016/S0002-9343(02)01049-5.CrossRefPubMed Grossman E, Messerli FH, Boyko V, Goldbourt U: Is there an association between hypertension and cancer mortality?. Am J Med. 2002, 112 (6): 479-486. 10.1016/S0002-9343(02)01049-5.CrossRefPubMed
15.
go back to reference Begg CB, Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 1994, 3 (2): 173-175.PubMed Begg CB, Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 1994, 3 (2): 173-175.PubMed
16.
go back to reference Goeman JJ, Buhlmann P: Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics. 2007, 23 (8): 980-987. 10.1093/bioinformatics/btm051.CrossRefPubMed Goeman JJ, Buhlmann P: Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics. 2007, 23 (8): 980-987. 10.1093/bioinformatics/btm051.CrossRefPubMed
17.
go back to reference Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010, 7 (5): 277-285. 10.1038/nrurol.2010.47.CrossRefPubMedPubMedCentral Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010, 7 (5): 277-285. 10.1038/nrurol.2010.47.CrossRefPubMedPubMedCentral
18.
go back to reference Jedlitschky G, Greinacher A, Kroemer HK: Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood. 2012, 119 (15): 3394-3402. 10.1182/blood-2011-09-336933.CrossRefPubMed Jedlitschky G, Greinacher A, Kroemer HK: Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood. 2012, 119 (15): 3394-3402. 10.1182/blood-2011-09-336933.CrossRefPubMed
19.
go back to reference Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadée W: Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004, 64 (12): 4294-4301. 10.1158/0008-5472.CAN-03-3884.CrossRefPubMed Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadée W: Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004, 64 (12): 4294-4301. 10.1158/0008-5472.CAN-03-3884.CrossRefPubMed
20.
go back to reference Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009, 69 (4): 1494-1501. 10.1158/0008-5472.CAN-08-2483.CrossRefPubMed Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009, 69 (4): 1494-1501. 10.1158/0008-5472.CAN-08-2483.CrossRefPubMed
21.
go back to reference Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996, 1242 (3): 201-210.PubMed Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996, 1242 (3): 201-210.PubMed
22.
go back to reference Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol. 2003, 170 (6 Pt1): 2163-2172.CrossRefPubMed Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol. 2003, 170 (6 Pt1): 2163-2172.CrossRefPubMed
23.
go back to reference Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR: Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008, 179 (5): 1704-1708. 10.1016/j.juro.2008.01.027.CrossRefPubMedPubMedCentral Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR: Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008, 179 (5): 1704-1708. 10.1016/j.juro.2008.01.027.CrossRefPubMedPubMedCentral
24.
go back to reference Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK: Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012, 61 (2): 258-268. 10.1016/j.eururo.2011.10.007.CrossRefPubMed Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK: Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012, 61 (2): 258-268. 10.1016/j.eururo.2011.10.007.CrossRefPubMed
25.
go back to reference Choueiri TK, Pomerantz MM, Signoretti S: Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013, 14 (2): 105-107. 10.1016/S1470-2045(12)70599-5.CrossRefPubMed Choueiri TK, Pomerantz MM, Signoretti S: Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013, 14 (2): 105-107. 10.1016/S1470-2045(12)70599-5.CrossRefPubMed
26.
go back to reference Begg CB, Gray R: Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika. 1984, 71 (1): 11-18. 10.1093/biomet/71.1.11.CrossRef Begg CB, Gray R: Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika. 1984, 71 (1): 11-18. 10.1093/biomet/71.1.11.CrossRef
Metadata
Title
Genomic investigation of etiologic heterogeneity: methodologic challenges
Authors
Colin B Begg
Venkatraman E Seshan
Emily C Zabor
Helena Furberg
Arshi Arora
Ronglai Shen
Jodi K Maranchie
Matthew E Nielsen
W Kimryn Rathmell
Sabina Signoretti
Pheroze Tamboli
Jose A Karam
Toni K Choueiri
A Ari Hakimi
James J Hsieh
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2014
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-14-138

Other articles of this Issue 1/2014

BMC Medical Research Methodology 1/2014 Go to the issue